1,754 karma · joined December 31, 2013
Title is misleading - this is a first in human, safety/dose-escalation study for this particular oncolytic virus. Oncolytic viruses have been in clinical development for quite some time. In response to the predictable “let us know when it works in humans” responses we see following sensationalist clinical research headlines, in 2015 we actually saw an oncolytic virus approved in the US: T-VEC for inoperable melanoma [0]
A few interesting things here from my point of view. First, they’re engineering the virus to infect cancer cells and overexpress PD-L1 to prime for enhanced immune-mediated killing. This could help a “cold” tumor turn “hot” by remodeling the tumor microenvironment. Second, the virus will also overexpress a symporter in the cancer cells which allows for targeted imaging and monitoring of tumor activity and cell death. There’s a nice graphical abstract available for reference [1]
Importantly, they’re assessing this in TNBC as it is associated with a very poor prognosis and has been validated as responsive to anti-PD-1 immunotherapies (eg, Keytruda/pembrolizumab)[2]
For the curious, there’s a preclinical Nature paper from June 2021 describing this in pancreatic cancer cells [3]
[0] https://en.wikipedia.org/wiki/Talimogene_laherparepvec
[1] https://pubmed.ncbi.nlm.nih.gov/35118191/
https://www.science.org/doi/10.1126/science.abl9283?cookieSe...
The PDF is not overwhelming - 7 or so slides max with a focus on visualizations over heavy text. It is worth the extra effort if you’re passionate about a specific role or organization.
The headline should read: “First patient dosed in Phase II trial of mRNA-based vaccine for colorectal cancer.”
[0] https://investors.biontech.de/news-releases/news-release-det...
[1] https://clinicaltrials.gov/ct2/results?cond=&term=RO7198457&...
[2] https://cancerres.aacrjournals.org/content/80/16_Supplement/...
[0] https://bigrigpros.com/why-do-semi-trucks-have-spikes-on-whe...
https://www.wnycstudios.org/podcasts/radiolab/articles/dirty...
Per an analysis of the report [1]:
“The U.S. spent $10,637 per capita on health care in 2018. Comparable countries spent $5,527.
The overwhelming majority of the difference — 76% of it — came from spending on inpatient and outpatient care — not drugs, which get more attention but represent just 10% of the difference.“
As someone who works in the pharmaceutical industry, I’ll be the first to admit that the financial toxicity associated with prescription drugs is a very real concern. To be absolutely clear, there is opportunity to reduce the cost for many prescription drugs without hobbling innovation. But perhaps the conversation would be better served by focusing on the larger system that allow healthcare costs to flourish unchecked? Should we not also be outraged when a single hospital-provided band-aid costs $7.00 (~20X markup)? [2] Price gouging is rampant across the board.
[0] https://www.healthsystemtracker.org/brief/what-drives-health...
[1] https://www.axios.com/drugs-arent-the-reason-the-us-spends-s...
[2] https://www.pri.org/stories/2017-10-16/curious-case-629-er-b...
The population obviously hasn't quadrupled since Yosemite closed to visitors on March 20th. It is remarkable though to see how quickly wildlife is willing to re-enter areas that have historically been overrun with humans!
And relevant Radiolab episode here: https://www.wnycstudios.org/story/267176-never-quite-now